GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-11. Numbers and descriptions here follow the published literature rather than marketing material.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
=== Further manifestations of solvent hydrogen bonding === Increase in the melting point, boiling point, solubility, and viscosity of many compounds can be explained by the concept of hydrogen bonding. Negative azeotropy of mixtures of HF and water. The fact that ice is less dense than liquid water is due to a crystal structure stabilized by hydrogen bonds. Dramatically higher boiling points of NH3, H2O, and HF compared to the heavier analogues PH3, H2S, and HCl, where hydrogen-bonding is absent. Viscosity of anhydrous phosphoric acid and of glycerol. Dimer formation in carboxylic acids and hexamer formation in hydrogen fluoride, which occur even in the gas phase, resulting in gross deviations from the ideal gas law. Pentamer formation of water and alcohols in apolar solvents.
=== Development === The series originated from discussions between Toho producers and Yeon Sang-ho in 2018, during which Yeon selected The Human Vapor from Toho's "Transforming Human Series" for its blend of speculative science and human drama. Yeon, known for global hits like Train to Busan (2016) and Netflix's Hellbound (2021), emphasized the original film's "skillful sci-fi expressions" and emotional core, stating: "While it is a sci-fi thriller, at its core, it is a story about people. We focused on treating human emotions with care and portraying the characters’ humanity." Script development took three years, with Ryu Yong-jae—Yeon's collaborator on Parasyte: The Grey (2024)—joining as co-writer. Shinzo Katayama, who was acclaimed for his directing live action TV seriesGannibal (2022), was selected as director for his ability to merge genre elements with intimate storytelling. Katayama, upon revisiting the original, noted: "I was intrigued by its blend of human drama and romantic elements, despite featuring an absurd creature like the Human Vapor." The project represents Netflix's first partnership with Toho, aiming to revive the studio's tokusatsu legacy for global audiences using cutting-edge VFX. Wow Point, the production company behind Parasyte: The Grey, co-produces, infusing Korean expertise in genre storytelling.
=== Plays === Habis, tragédie (1714) Cléarque, tyran d'Héraclée, tragédie (1733 - English translation: Cléarchus, Tyrant of Heraclea, a tragedy) Marsidie reine des Cimbres, tragédie (1735 - English translation: Marsidie, Queen of the Cimbri) Semiramis, tragédie (1737 - English translation: Semiramis, tragedy)
Solid-liquid extraction based ambient ionization is based on the use of a charged spray, for example electrospray to create a liquid film on the sample surface. Molecules on the surface are extracted into the solvent. The action of the primary droplets hitting the surface produces secondary droplets that are the source of ions for the mass spectrometer. Desorption electrospray ionization (DESI) is one of the original ambient ionization sources and uses an electrospray source to create charged droplets that are directed at a solid sample. The charged droplets pick up the sample through interaction with the surface and then form highly charged ions that can be sampled into a mass spectrometer. Desorption atmospheric pressure photoionization (DAPPI) is a solid-liquid extraction ambient ionization method that enables the direct analysis of samples deposited on surfaces by means of a jet of hot solvent vapour and ultraviolet light. The hot jet thermally desorbs the sample from a surface and the vaporized sample is ionized by a vacuum ultraviolet light and consequently sampled into a mass spectrometer.
Episode Two was released for Windows, Xbox 360 and PlayStation 3 on October 10, 2007, as part of the compilation The Orange Box. It was distributed digitally on Steam and at retail by Electronic Arts. Episode Two focuses on expansive environments, travel and less linear play. As Freeman, the player travels with Alyx into the surrounding countryside, pursued by Combine forces. Episode Two's new technologies and gameplay features were praised by reviewers; however, though it was significantly longer than Episode 1, the length was again a point of criticism.
Sources: en.wikipedia.org
=== Epilepsy === Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms. It has also been successfully given intravenously to treat status epilepticus. In the US, valproic acid is also prescribed as an anti-epileptic drug indicated for the treatment of manic episodes associated with bipolar disorder; monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in people with multiple seizure types that include absence seizures.
The plant would be capable of converting natural gas into a liquid form that can be trucked to consumers. The project will create between 700 and 2,800 jobs in the region. In May 2019, Minister McNaughton announced that the Ontario government "committed up to $63.7 million" to Southwestern Integrated Fibre Technology (SWIFT) with support from other levels of government. The not-for-profit, publicly-funded SWIFT project to develop a regional fibre optic network, has been one of the key initiatives of the Western Ontario Wardens' Caucus (WOWC) representing upper-tier municipalities in southern Ontario from Dufferin to Windsor. Through SWIFT, federal, provincial and local municipalities "subsidize the construction of an open-access, high-speed broadband network in Southwestern Ontario, Caledon and the Niagara Region." In December 2025, Ford and Niagara Falls mayor Jim Diodati announced a new tourism strategy for the city, including expanded transportation and entertainment offerings such as new "attractions, gaming, wine and restaurants, and arts and culture." In early 2026, Ford announced plans to build a new 2-million square foot convention centre in Toronto, replacing the Metro Toronto Convention Centre. He later also announced plans to take control of the Billy Bishop Toronto City Airport to expand its runway and allow jets at the island airport, a suggestion immediately supported by the Toronto Port Authority. Expansion remains opposed by local Councillors, local community associations and the "NoJetsTo" and "Parks Not Planes" advocacy groups.
== History == GeneDx was founded in 2000 by scientists Sherri Bale and John Compton from the National Institutes of Health (NIH). The company was established to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which limited commercial testing options existed at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, GeneDx was acquired by BioReference Laboratories and continued to operate as a subsidiary. In October 2016, Benjamin D. Solomon was appointed as managing director. In 2021, Katherine Stueland became CEO of GeneDx. GeneDx was acquired by Sema4 in 2022, and Stueland was named CEO of the combined company. In 2023, the combined company underwent a strategic transformation, refocusing on whole exome and genome sequencing in pediatrics, and changed its name to GeneDx. In 2025 GeneDx was named one of Fast Company's Most Innovative Companies, ranked No.2 in the Biotech category. The recognition highlighted the company's work in advancing genomic sequencing and data-driven approaches to improve rare disease diagnosis. GeneDx settled a patent dispute with Myriad Genetics in February 2015 after GeneDx launched a BRCA mutation breast cancer genetic screening test following the US Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. that concluded isolated gene sequences were patent ineligible.
== External links == Peltola; et al. (2004). "News on cereulide, the emetic toxin of Bacillus Cereus". Appl Env Microbiol. 70 (8): 4996–5004.{{cite journal}}: CS1 maint: deprecated archival service (link) S. Pitchayawasin; M. Isobe; M. Kuse; T. Franz; N. Agata; M. Ohta (May 19, 2004). "Molecular diversity of cereulide" (PDF). International Journal of Mass Spectrometry. 235: 123–129. ISSN 1387-3806. Archived from the original (PDF) on March 13, 2005.
=== DNA damage === Aging is the most important risk factor for cardiovascular problems. The causative basis by which aging mediates its impact, independently of other recognized risk factors, remains to be determined. Evidence has been reviewed for the key role of DNA damage in vascular aging. 8-oxoG, a common type of oxidative damage in DNA, is found to accumulate in plaque vascular smooth muscle cells, macrophages and endothelial cells, thus linking DNA damage to plaque formation. DNA strand breaks also increased in atherosclerotic plaques. Werner syndrome (WS) is a premature aging condition in humans. WS is caused by a genetic defect in a RecQ helicase that is employed in several repair processes that remove damage from DNA. WS patients develop a considerable burden of atherosclerotic plaques in their coronary arteries and aorta: calcification of the aortic valve is also frequently observed. These findings link excessive unrepaired DNA damage to premature aging and early atherosclerotic plaque development (see DNA damage theory of aging).
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.